About US
Contact us
-
FDA accepts Eisai’s sNDA to review antiepileptic drug FycompaJapan-based Eisai has obtained approval for review from US Food and Drug Administration (FDA) for its antiepileptic drug Fycompa (perampanel). The FDA accepted Eisai's supplemental new drug applicati2014/10/23
-
Sanofi Pasteur and Immune Design to develop vaccine for herpes simplex virusVaccines division Sanofi Pasteur has partnered with clinical-stage immunotherapy company Immune Design to develop herpes simplex virus (HSV) immune therapy. As part of the deal, both companies will d2014/10/22
-
AstraZeneca and University of Cambridge partner for research on neurodegenerative diseasesAstraZeneca and subsidiary MedImmune have entered into four new collaborations with the University of Cambridge, expanding on their existing partnership. As part of the three year collaboration, both2014/10/22
-
UPDATED: FDA panel say Pfizer's Chantix should continue to wear a 'black box' labelPfizer's ($PFE) controversial smoking-cessation drugChantixwill continue to be stuck with a black-box warning label at least until late next year, assuming the U.S. Food and Drug Administration follow2014/10/21
-
Ranbaxy to pay $40m to settle overcharging Texas Medicaid programme litigationIndia-based drug maker Ranbaxy Laboratories has agreed to pay $39.75m to settle litigation about its participation in Texas Medicaid, a US health care programme for people with low incomes. The compa2014/10/21
-
Genentech's IPF-treating drug Esbriet receives FDA approvalRoche Group subsidiary Genentech has received approval from US Food and Drug Administration (FDA) for Esbriet (pirfenidone) drug to treat patients with idiopathic pulmonary fibrosis (IPF). Esbriet is2014/10/20
-
Baxter prepping for HyQvia launch with spinoff's success on the lineIt's been a long road for Baxter's ($BAX) primary immunodeficiency (PID) replacement therapy in the U.S., but the Illinois company is finally preparing to roll out the med in its home country. And wit2014/10/20
-
ViiV Healthcare’s HIV drug Triumeq obtains Canadian approvalViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer and Shionogi, has obtained approval in Canada, for its Triumeq (dolutegravir) 50mg, abacavir 600mg, and lamivudine 300mg) to treat pat2014/10/17
-
Gilead’s Harvoni receives FDA approval for hepatitis C genotype 1 infectionGilead Sciences has received approval from US Food and Drug Administration for Harvoni (ledipasvir 90mg/sofosbuvir 400mg), a once-daily single tablet regimen to treat chronic hepatitis C genotype 1 in2014/10/17
-
WHO warns of 10,000 new weekly Ebola casesThe World Health Organisation (WHO) has warned West Africa may face up to 10,000 new Ebola cases per week within two months, due to the increasing number of patients. With a reported death rate of 702014/10/17